



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



CGP 7930

Item No. 29429

CAS Registry No.: 57717-80-3
Formal Name: 3,5-bis(1,1-dimethylethyl)-4-hydroxy- β,β -dimethyl-benzenepropanol
MF: $C_{19}H_{32}O_2$
FW: 292.5
Purity: $\geq 98\%$
Supplied as: A crystalline solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CGP 7930 is supplied as a crystalline solid. A stock solution may be made by dissolving the CGP 7930 in the solvent of choice, which should be purged with an inert gas. CGP 7930 is soluble in organic solvents such as ethanol and DMSO. The solubility of CGP 7930 in these solvents is approximately 100 mM.

Description

CGP 7930 is a positive allosteric modulator of GABA_B receptors.¹ It enhances GABA binding with a maximal effect of 143% compared to a GABA-only control in CHO cells membranes expressing the GABA_{B(1b/2)} receptor and enhances GABA binding to rat cortical membranes when used at a concentration of 30 μ M. It is selective for GABA binding to heterodimeric GABA_{B(1b/2)} over monomeric GABA_{B(1b)} receptors. CGP 7930 potentiates the efficacy of the GABA_B receptor agonist baclofen (Item No. 27326) in decreasing the spontaneous firing rate of dopaminergic neurons in the rat ventral tegmental area (VTA) *in vitro* ($EC_{50} = 0.27 \mu$ M).² It also potentiates the sedative-reducing effects induced by the GABA_B receptor agonists baclofen and γ -hydroxybutyric acid (GHB) in rats when administered at doses ranging from 10 to 170 mg/kg, effects that can be blocked by the GABA_B receptor antagonist SCH 50911.³ CGP 7930 reduces self-administration of nicotine, alcohol, and cocaine in rodent models.⁴ It suppresses the acquisition of alcohol drinking behavior in alcohol-naïve Sardinian alcohol-preferring rats over a five-day period when administered at doses ranging from 25 to 100 mg/kg and transiently reduces the maintenance of alcohol drinking behavior in alcohol-experienced rats at a dose of 100 mg/kg.⁵

References

1. Urwyler, S., Mosbacher, J., Lingenhoehl, K., *et al.* Positive allosteric modulation of native and recombinant γ -aminobutyric acid_B receptors by 2,6-di-*tert*-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. *Mol. Pharmacol.* **60(5)**, 963-971 (2001).
2. Chen, Y., Phillips, K., Minton, G., *et al.* GABA_B receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area. *Br. J. Pharmacol.* **144(7)**, 926-932 (2005).
3. Carai, M.A.M., Colombo, G., Froestl, W., *et al.* In vivo effectiveness of CGP7930, a positive allosteric modulator of the GABA_B receptor. *Eur. J. Pharmacol.* **504(3)**, 213-216 (2004).
4. Adams, C.L. and Lawrence, A.J. CGP7930: A positive allosteric modulator of the GABA_B receptor. *CNS Drug Rev.* **13(3)**, 308-316 (2007).
5. Orrù, A., Lai, P., Lobina, C., *et al.* Reducing effect of the positive allosteric modulators of the GABA_B receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. *Eur. J. Pharmacol.* **525(1-3)**, 105-111 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/13/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM